Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 5OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Ovarian Neoplasms 7Uterine Cervical Neoplasms 2Rectal Neoplasms 2Endometrial Neoplasms 2Uveal Melanoma 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Pleural Effusion, Malignant 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Leiomyosarcoma 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Temozolomide 85Radiotherapy 51Bevacizumab 31Irinotecan 19Radiation 16Carmustine 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14O(6)-benzylguanine 11Chemotherapy, Adjuvant 11Carboplatin 9sargramostim 8Thalidomide 8Imatinib Mesylate 8Filgrastim 8Surgical Procedures, Operative 6Gene Expression Profiling 6Drug Therapy 6pembrolizumab 5aldesleukin 5Topotecan 5Radiotherapy, Intensity-Modulated 5Hydroxyurea 5Gefitinib 5Etoposide 5Sorafenib 4Immunohistochemistry 4Dasatinib 4Celecoxib 4Biopsy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gliosarcoma × cediranib × Clear all
NCT01310855 2017-05-31

Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma

University College, London

Phase 2 Terminated
38 enrolled 8 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡